Expression of MicroRNAs in Thyroid Carcinoma

Zhu, Gaohong; Xie, Lijun; Miller, Daniel G.

doi:10.1007/978-1-4939-7046-9_19

Cited by 18 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past few years, several studies have focused on the expression profiles and biological roles of miRNA in PTC 17,33,34. An increasing number of miRNAs have been found to be dysregulated in PTC, and their dysregulation is believed to have important impacts on the formation and progression of PTC via a negative regulation of their target genes implicated in cellular biological behaviors 19,35,36. Hence, further investigation of the detailed roles of specific miRNAs in PTC might facilitate the identification of more effective targets for the treatment of patients with PTC.…”

Section: Discussionmentioning

confidence: 99%

<p>microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1</p>

Song

Yang

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Accumulating evidence has revealed that an increasing number of microRNAs (miRNAs) are dysregulated in papillary thyroid cancer (PTC) and that their dysregulation plays an important role in PTC onset and progression. Reportedly, miRNA-564 (miR-564) is downregulated in several types of human cancer. However, its expression profile and specific functions in PTC remain unclear to date. Methods: In this study, we used reverse transcription-quantitative polymerase chain reaction to detect miR-564 expression in PTC tissues and cell lines. Further, the regulatory roles of miR-564 in the malignant development of PTC in vitro and in vivo were examined using a series of functional experiments. In addition, the possible underlying mechanisms and signaling pathways involved were investigated. Results: We demonstrated that miR-564 expression markedly decreased in PTC tissues and cell lines, and this decrease correlated with the lymph node metastasis and tumor–node–metastasis stage. miR-564 upregulation significantly inhibited cell proliferation, migration, and invasion and induced cell apoptosis in vitro as well as hindered tumor growth in vivo. Furthermore, astrocyte-elevated gene-1 (AEG-1) was identified as a direct target gene of miR-564 in PTC cells. Its expression was upregulated and inversely correlated with miR-564 expression in clinically PTC tissues. Additionally, the silencing of AEG-1 expression could imitate the action of miR-564 overexpression in PTC cells. Remarkably, the restoration of AEG-1 expression partially abolished the tumor-suppressing effects induced by a miR-564 upregulation in PTC cells. Ectopic miR-564 expression deactivated the PTEN/Akt pathway in PTC cells in vitro and in vivo. Conclusion: Overall, the findings of the current study suggest that miR-564 is a tumor-suppressive miRNA that exerts crucial roles in the development and progression of PTC. Therefore, this miRNA might be a promising candidate target in the anticancer treatment of patients with PTC.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1</p>

Song

Yang

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…In recent years, many miRNA signatures have been well characterized for PTC (17); however, but further investigation on the roles of dysregulated miRs in PTC development and progression is necessary for seeking more effective therapeutic strategies. In the present study, it was observed that miR-409-3p was frequently downregulated in PTC samples specimens and cell lines, consistent with its reduced expression in lung (18) and bladder cancer (19).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑409‑3p suppresses cell proliferation and cell cycle progression by targeting cyclin D2 in papillary thyroid carcinoma

et al. 2018

View full text Add to dashboard Cite

MicroRNAs (miRs) function as tumor suppressors or oncogenes in tumor development and progression. The present study reported that miR-409-3p was significantly downregulated in human papillary thyroid carcinoma (PTC) tissues and cell lines. Overexpression of miR-409-3p suppressed cell proliferation and induced cell cycle G/G phase arrest in PTC cells. Further study revealed that the transcriptional regulator cyclin D2 was a target of miR-409-3p, as miR-409-3p bound directly to its 3'-untranslated region and the miR-409-3p mimic reduced the protein expression levels of cyclin D2. In addition, restoration of cyclin D2 expression reversed the inhibitive effect of miR-409-3p on PTC cells. To the best of our knowledge, these findings demonstrate for the first time that miR-409-3p functions as a tumor suppressor in PTC and could serve as an efficient agent for therapy of PTC.

show abstract

“…Previous studies have reported that miRNAs are aberrantly expressed in almost all types of human cancer, including PTC (12), colorectal cancer (13), lung cancer (14), glioblastoma (15) MicroRNA-766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway and bladder cancer (16). Increasing evidence has revealed that various miRNAs are differentially expressed in PTC, and their dysregulation has been implicated in the regulation of PTC occurrence and development (17)(18)(19). Furthermore, miRNAs may have tumor suppressive or oncogenic roles in the progression of PTC and are able to regulate various cancer-associated biological processes, including cell proliferation, cell cycle progression, apoptosis, invasion, metastasis and epithelial-mesenchymal transition (20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway

Zhao

Chen

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs) are widely dysregulated in papillary thyroid cancer (PTC). Dysregulated miRNAs, together with their target genes, comprise a complex network that has been implicated in the regulation of PTC pathogenesis. Further knowledge of the functional roles of aberrantly expressed miRNAs in PTC, and the underlying molecular mechanisms, may assist in the identification of novel therapeutic targets. miR-766 has been well studied in human cancer; however, the expression status, specific roles and regulatory mechanisms of miR-766 in PTC remain unclear. The present study aimed to detect miR-766 expression in PTC tissues and cell lines, to explore the biological roles of miR-766 in the malignant biological behaviors of PTC cells, and to determine the underlying mechanism of action of miR-766 in PTC cells. The results revealed that miR-766 was downregulated in PTC tissues and cell lines, and its downregulation was strongly associated with TNM stage and lymph node metastasis. Overexpression of miR-766 inhibited PTC cell proliferation, colony formation, migration and invasion, promoted cell apoptosis and reduced tumor growth in vivo. Mechanistically, insulin receptor substrate 2 (IRS2) was identified as a direct target of miR-766 in PTC cells. IRS2 was upregulated in PTC tissues, and this was inversely correlated with miR-766 expression. Inhibition of IRS2 simulated the tumor suppressor activity of miR-766 in PTC cells. Restoration of IRS2 expression negated the tumor-suppressing effects of miR-766 overexpression on PTC cells. Notably, miR-766 directly targeted IRS2 to inhibit activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in PTC cells in vitro and in vivo. Overall, these findings indicated that miR-766 may inhibit the malignant biological behaviors of PTC cells by directly targeting IRS2 and regulating the PI3K/Akt pathway, thus suggesting that this miRNA may be a promising therapeutic target for PTC.

show abstract

Expression of MicroRNAs in Thyroid Carcinoma

Cited by 18 publications

References 73 publications

<p>microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1</p>

<p>microRNA-564 inhibits the aggressive phenotypes of papillary thyroid cancer by directly targeting astrocyte-elevated gene-1</p>

MicroRNA‑409‑3p suppresses cell proliferation and cell cycle progression by targeting cyclin D2 in papillary thyroid carcinoma

MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway

Contact Info

Product

Resources

About